Page last updated: 2024-09-03

jolkinolide b and Bladder Cancer

jolkinolide b has been researched along with Bladder Cancer in 2 studies

Research

Studies (2)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's0 (0.00)24.3611
2020's2 (100.00)2.80

Authors

AuthorsStudies
Fan, RZ; Gan, L; Huang, JL; Li, W; Lin, ZJ; Sang, J; Tang, GH; Yin, S; Zou, MF1
Diao, HJ; Fan, RZ; Gan, L; Huang, JL; Li, W; Sang, J; Tang, GH; Yin, S; Zou, MF1

Other Studies

2 other study(ies) available for jolkinolide b and Bladder Cancer

ArticleYear
Jolkinolide B sensitizes bladder cancer to mTOR inhibitors via dual inhibition of Akt signaling and autophagy.
    Cancer letters, 2022, 02-01, Volume: 526

    Topics: Animals; Autophagy; Cell Line, Tumor; Diterpenes; Drugs, Chinese Herbal; Humans; Male; Mice; MTOR Inhibitors; Proto-Oncogene Proteins c-akt; Signal Transduction; Transfection; Urinary Bladder Neoplasms

2022
Jolkinolide B targets thioredoxin and glutathione systems to induce ROS-mediated paraptosis and apoptosis in bladder cancer cells.
    Cancer letters, 2021, 07-01, Volume: 509

    Topics: Animals; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cell Line, Tumor; Cell Proliferation; Cisplatin; Diterpenes; Drug Resistance, Neoplasm; Endoplasmic Reticulum Stress; Enzyme Inhibitors; Extracellular Signal-Regulated MAP Kinases; Glutathione; Humans; Male; Mice, Inbred BALB C; Mice, Nude; Reactive Oxygen Species; Thioredoxin Reductase 1; Thioredoxins; Urinary Bladder Neoplasms; Xenograft Model Antitumor Assays

2021